Crossmark

A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) — a randomised feasibility study using the trial within a cohort (TwiC) methodology

Crossref DOI link: https://doi.org/10.1186/s40814-022-01156-3

Published Online: 2022-09-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bibby, Anna C. http://orcid.org/0000-0001-7386-7754
Zahan-Evans, Natalie

Keenan, Emma

Comins, Charles

Harvey, John E.

Day, Helen

Rahman, Najib M.

Fallon, Janet E.

Gooberman-Hill, Rachael

Maskell, Nick A.
Funding

Funding for this research was provided by:

National Institute for Health Research (DRF-2016-09-065)
License Information

Text and Data Mining valid from 2022-09-03

Version of Record valid from 2022-09-03
More Information

Article History

Received: 9 July 2021

Accepted: 24 August 2022

First Online: 3 September 2022

Declarations

:

: ASSESS-meo and TILT were both approved by NHS Research Ethics Committees (ref 17/SW/0019 and 17/SW/0080, respectively) and the HRA (IRAS ID 220360 and 215394, respectively). TILT was also approved by the MHRA (ref 18524/0228/001–0002). Participants in both studies provided written informed consent to participate.

: Consent to publication was included in participants’ consent to participate in the trial.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below